questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Phosphotransferases
Phosphotransferases (Phosphate Group Acceptor)
Phosphotransferases (Phosphate Group Acceptor) : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases (Phosphate Group Acceptor) : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases (Phosphate Group Acceptor) : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases (Phosphate Group Acceptor) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-31",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphotransferases",
"url": "https://questionsmedicales.fr/mesh/D010770",
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases",
"code": {
"@type": "MedicalCode",
"code": "D010770",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adenylate kinase",
"alternateName": "Adenylate Kinase",
"url": "https://questionsmedicales.fr/mesh/D000263",
"about": {
"@type": "MedicalCondition",
"name": "Adenylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D000263",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "ATP synthetase complexes",
"alternateName": "ATP Synthetase Complexes",
"url": "https://questionsmedicales.fr/mesh/D025181",
"about": {
"@type": "MedicalCondition",
"name": "ATP synthetase complexes",
"code": {
"@type": "MedicalCode",
"code": "D025181",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Guanylate kinase",
"alternateName": "Guanylate Kinases",
"url": "https://questionsmedicales.fr/mesh/D051528",
"about": {
"@type": "MedicalCondition",
"name": "Guanylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D051528",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside diphosphate kinase",
"alternateName": "Nucleoside-Diphosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009701",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside diphosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009701",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NM23 Nucleoside Diphosphate kinases",
"alternateName": "NM23 Nucleoside Diphosphate Kinases",
"url": "https://questionsmedicales.fr/mesh/D054778",
"about": {
"@type": "MedicalCondition",
"name": "NM23 Nucleoside Diphosphate kinases",
"code": {
"@type": "MedicalCode",
"code": "D054778",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside phosphate kinase",
"alternateName": "Nucleoside-Phosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009703",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside phosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009703",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.575"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"alternateName": "Phosphotransferases (Phosphate Group Acceptor)",
"code": {
"@type": "MedicalCode",
"code": "D017856",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch."
}
},
{
"@type": "Person",
"name": "Zengqi Xie",
"url": "https://questionsmedicales.fr/author/Zengqi%20Xie",
"affiliation": {
"@type": "Organization",
"name": "Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China."
}
},
{
"@type": "Person",
"name": "Bernhard Erni",
"url": "https://questionsmedicales.fr/author/Bernhard%20Erni",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Yulin Zhu",
"url": "https://questionsmedicales.fr/author/Yulin%20Zhu",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
},
{
"@type": "Person",
"name": "Feng He",
"url": "https://questionsmedicales.fr/author/Feng%20He",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Closed loop deep brain stimulation: A systematic scoping review.",
"datePublished": "2022-11-06",
"url": "https://questionsmedicales.fr/article/36356439",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clineuro.2022.107516"
}
},
{
"@type": "ScholarlyArticle",
"name": "Incidence of traumatic brain injuries in head-injured children with seizures.",
"datePublished": "2022-11-02",
"url": "https://questionsmedicales.fr/article/36323396",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1742-6723.14112"
}
},
{
"@type": "ScholarlyArticle",
"name": "Data-driven discovery of canonical large-scale brain dynamics.",
"datePublished": "2022-11-02",
"url": "https://questionsmedicales.fr/article/36479448",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/texcom/tgac045"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mucosal Immunity and the Gut-Microbiota-Brain-Axis in Neuroimmune Disease.",
"datePublished": "2022-11-01",
"url": "https://questionsmedicales.fr/article/36362150",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms232113328"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sex-specific transcriptional rewiring in the brain of Alzheimer's disease patients.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36389068",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fnagi.2022.1009368"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphotransferases",
"item": "https://questionsmedicales.fr/mesh/D010770"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"item": "https://questionsmedicales.fr/mesh/D017856"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases (Phosphate Group Acceptor) - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Comment diagnostiquer une déficience en phosphotransférases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphotransférases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nPeut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Brain+Ischemia&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les symptômes d'une déficience en phosphotransférases ?\nLes troubles neurologiques sont-ils liés aux phosphotransférases ?\nComment les symptômes varient-ils selon le type d'enzyme ?\nLes symptômes apparaissent-ils à la naissance ?\nY a-t-il des symptômes spécifiques aux enfants ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Brain+Ischemia&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Peut-on prévenir les déficiences en phosphotransférases ?\nLes tests de dépistage néonatal sont-ils utiles ?\nY a-t-il des recommandations diététiques préventives ?\nLes conseils génétiques sont-ils importants ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Brain+Ischemia&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à traiter ces déficiences ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la gestion diététique aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Brain+Ischemia&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes troubles cardiaques sont-ils une complication possible ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Brain+Ischemia&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les facteurs de risque pour ces déficiences ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'alimentation peut-elle influencer le risque ?\nLes infections peuvent-elles aggraver la condition ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Brain+Ischemia&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphotransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour évaluer l'activité des phosphotransférases."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphotransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de dosage enzymatique et les analyses de métabolites sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes métaboliques, comme la fatigue ou des troubles énergétiques, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les phosphotransférases."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphotransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, faiblesse musculaire, troubles de la croissance et anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux phosphotransférases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent de l'enzyme spécifique affectée et de son rôle métabolique."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils à la naissance ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent apparaître à la naissance, tandis que d'autres se développent plus tard."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux enfants ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent présenter des retards de développement et des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en phosphotransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage néonatal sont-ils utiles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage néonatal peuvent identifier certaines déficiences précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques préventives ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recommandations diététiques peuvent être établies pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les déficiences, mais protègent contre les infections."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments nutritionnels et une gestion diététique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces déficiences."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à traiter ces déficiences ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à gérer les symptômes, mais ne corrigent pas la déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études cliniques explorent de nouvelles approches thérapeutiques pour ces conditions."
}
},
{
"@type": "Question",
"name": "Comment la gestion diététique aide-t-elle ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion diététique peut aider à compenser les déficiences métaboliques et à améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces déficiences ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques, neurologiques et de croissance peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les troubles cardiaques sont-ils une complication possible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cardiaques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies métaboliques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des déficiences en phosphotransférases peuvent avoir un risque accru de maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour ces déficiences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies auto-immunes peuvent affecter le métabolisme et augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée peut exacerber les symptômes chez les personnes à risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la condition ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher ou aggraver les symptômes liés aux déficiences enzymatiques."
}
}
]
}
]
}
At the turn of the 21st century, closed-loop deep brain stimulation (CL-DBS) systems have emerged as promising neuromodulatory treatment strategies, that integrate real-time feedback based on the brai...
A systematic literature search was conducted in seven major databases with various keywords relating to CL-DBS, for non-randomised cohort studies, finalised clinical trials, case reports, and nonrando...
Seven studies satisfied our inclusion criteria. Six investigated the use of CL-DBS therapy for neurological disorders, while one investigated its use for psychiatric disorders. The average patient age...
To date, there is insufficient evidence that CL-DBS offers significant superior clinical outcomes over OL-DBS. Our scoping review suggests that CL-DBS can improve symptoms of specific neurological and...
Incidence and short-term outcomes of clinically important traumatic brain injury (ciTBI) in head-injured children presenting to ED with post-traumatic seizure (PTS) is not described in current literat...
Planned secondary analysis of a prospective observational study undertaken in 10 Australasian Paediatric Research in Emergency Departments International Collaborative (PREDICT) network EDs between 201...
Of 20 137 head injuries, 336 (1.7%) had PTS with median age of 4.8 years. Initial GCS was 15 in 268/336 (79.8%, AR -16.1 [95% CI -20.4 to -11.8]), 14 in 24/336 (7.1%, AR 4.4 [95% CI 1.6-7.2]) and ≤13 ...
PTS was uncommon in head-injured children presenting to the ED but associated with an increased risk of ciTBI in those with reduced GCS on arrival....
Human behavior and cognitive function correlate with complex patterns of spatio-temporal brain dynamics, which can be simulated using computational models with different degrees of biophysical realism...
Recent advances in next-generation sequencing (NGS) technologies have opened the door to a wellspring of information regarding the composition of the gut microbiota. Leveraging NGS technology, early m...
Sex-specific differences may contribute to Alzheimer's disease (AD) development. AD is more prevalent in women worldwide, and female sex has been suggested as a disease risk factor. Nevertheless, the ...
Diabetes mellitus (DM) is now recognized as a system-wide, autoimmune, inflammatory, microvascular disorder, which, in the retina and brain results in severe multifocal injury now recognized as a lead...
Age-related cortical atrophy, approximated by cortical thickness measurements from magnetic resonance imaging, follows a characteristic pattern over the lifespan. Although its determinants remain unkn...
Brain cancer is regarded among the deadliest forms of cancer worldwide. The distinct tumor microenvironment and inherent characteristics of brain tumor cells virtually render them resistant to the maj...
The development of effective treatments to prevent and slow Alzheimer's disease (AD) pathogenesis is needed in order to tackle the steady increase in the global prevalence of AD. This challenge is com...
Brain plasticity and metabolism are tightly connected by a constant influx of peripheral glucose to the central nervous system in order to meet the high metabolic demands imposed by neuronal activity....